

9. (amended) The chemical compound of claim 3, wherein the first and second hsp-binding moieties are geldanamycin.

12. (amended) A method for destruction of cells expressing a HER-family tyrosine kinase, comprising administering to the cells a chemical compound [according to any of claims 1-11] comprising first and second hsp-binding moieties which bind to the pocket of hsp90 with which ansamycin antibiotics bind, said binding moieties being connected to one another by a linker, wherein the first and second hsp-binding moieties are each an ansamycin antibiotic.

13. (amended) A method for treating cancer in a patient suffering from cancer, comprising administering to the patient a therapeutic composition comprising a chemical compound comprising first and second hsp-binding moieties which bind to the pocket of hsp90 with which ansamycin antibiotics bind, said binding moieties being connected to one another by a linker, wherein the first and second hsp-binding moieties are each an ansamycin antibiotic.

Please add claims 15-29 as follows:

15. The method according to claim 13, wherein at least one of the hsp-binding moieties is geldanamycin.

16. The method according to claim 15, wherein the linker has a length of 4 to 7 carbon atoms.

17. The method according to claim 16, wherein the linker has a length of 4 carbon atoms.

18. The method according to claim 13, wherein the first and second binding moieties are geldanamycin.

19. The method according to claim 18, wherein the linker has a length of 4 to 7 carbon atoms.
20. The method according to claim 19, wherein the linker has a length of 4 carbon atoms.
21. The method according to claim 14, wherein at least one of the hsp-binding moieties is geldanamycin.
22. The method according to claim 21, wherein the linker has a length of 4 to 7 carbon atoms.
23. The method according to claim 22, wherein the linker has a length of 4 carbon atoms.
24. The method according to claim 12, wherein the first and second binding moieties are geldanamycin.
- 
25. The method according to claim 24, wherein the linker has a length of 4 to 7 carbon atoms.
26. The method according to claim 25, wherein the linker has a length of 4 carbon atoms.
27. The method according to claim 12, wherein at least one of the hsp-binding moieties is geldanamycin.